Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults
Bharati Kochar, Virginia Pate, Michael D. Kappelman, Millie D. Long, Ashwin N. Ananthakrishnan, Andrew T. Chan, Robert S. Sandler
Topics & Concepts
MedicineVedolizumabHazard ratioInternal medicineCohortConfidence intervalPropensity score matchingRetrospective cohort studyOdds ratioCohort studyInflammatory bowel diseaseProportional hazards modelDiseaseInflammatory Bowel DiseaseClostridium difficile and Clostridium perfringens researchMicroscopic Colitis